Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(18)32930-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Randomized Evaluation of the PET-Adjusted IMRT for NSCLC Trial (REPAINT).
Int J Radiat Oncol Biol Phys
January 2025
Montefiore Einstein Comprehensive Cancer Center, Bronx, NY.
Background: Standard radiotherapy (RT) for locally advanced NSCLC (LA-NSCLC) employs a uniform dose of approximately 60 Gy. Recent trials demonstrated that radiotherapy dose escalation may not improve outcomes and may cause added toxicity. XXX previously performed a single-arm trial testing a personalized, risk-adapted, and de-intensified RT strategy.
View Article and Find Full Text PDFCentral Neck Dissection in Papillary Thyroid Carcinoma: Benefits and Doubts in the Era of Thyroid Lobectomy.
Biomedicines
September 2024
Department of Otorhinolaryngology and Head and Neck Surgery, European Institute of Oncology (IEO), IRCCS, 20141 Milan, Italy.
Introduction: Surgery is still the main line of treatment for papillary thyroid cancer (PTC) with a current trend for de-intensified treatment based on an excellent prognosis. The role of a routine prophylactic central neck dissection (PCND) is still debated as its impact on oncologic outcomes has never been cleared by a randomized clinical trial. In this study, we aimed to report our long-standing experience in PCND and its potential contemporary role in the treatment of PTC.
View Article and Find Full Text PDFOncologic surveillance after surgical treatment for clinically localized kidney cancer: UroCCR study n. 129.
Minerva Urol Nephrol
October 2024
Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France -
Background: In 2021, the EAU Guidelines implemented a novel, expert opinion-based follow-up scheme, with a three-risk-category system for clear cell (cc) and non-cc renal cell carcinoma (non-ccRCC) after surgery with curative intent. We aimed to validate the novel follow-up scheme and provide data-driven recurrence estimates according to risk groups, to confirm or implement the oncologic surveillance strategy.
Methods: We identified 5,320 patients from a prospectively maintained database involving 28 French referral centers.
Dose Deintensified 3-Day Photon, Proton, or Brachytherapy: A Nonrandomized Controlled Partial Breast Irradiation Trial.
Int J Radiat Oncol Biol Phys
February 2025
Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Purpose: The optimal approach for partial breast irradiation (PBI) is unknown. We investigated a novel de-intensified 3-fraction PBI regimen for photons, protons, and brachytherapy.
Methods And Materials: A multicenter nonrandomized controlled trial with the primary outcome of adverse cosmesis at 3 years versus before PBI.
De-intensification of postoperative radiotherapy in head and neck cancer irrespective of human papillomavirus status-results of a prospective multicenter phase II trial (DIREKHT Trial).
Front Oncol
August 2024
Department of Radiotherapy and Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Background: Current standard treatment concepts in head and neck squamous cell carcinoma (HNSCC) are based on former studies using 2D and 3D treatment plans. However, modern radiation techniques allow for a more precise and individual dose application. Therefore, in a clearly defined patient population, de-intensified risk-adapted radiation is investigated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!